Tatyana Batysheva

Dr. Tatyana Batysheva


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
NZNikolay Zavadenko
Nikolay Zavadenko
NSN.Y. Suvorinova
N.Y. Suvorinova
TBTatyana Batysheva
Tatyana Batysheva
OBO.V. Bykova
O.V. Bykova
APA.N. Platonova
A.N. Platonova
NMN.E. Maximova
N.E. Maximova
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить эффективность и безопасность двух режимов дозирования препарата Мексидол таблетки, покрытые пленочной оболочкой, 125 мг (ООО «НПК «ФАРМАСОФТ», Россия), по сравнению с плацебо, у детей с синдромом дефицита внимания с гиперактивностью (СДВГ) в возрасте от 6 до 12 лет. МАТЕРИАЛ И МЕТОДЫ Исследование проводили в 14 клинических центрах Российской Федерации как многоцентровое рандомизированное двойное слепое плацебо-контролируемое в 3 параллельных группах. В исследовании участвовали 333 ребенка в возрасте от 6 до 12 лет с подтвержденным диагнозом СДВГ, установленным в соответствии с критериями МКБ-10 и DSM-5. После скрининга (до 14 дней) пациенты были рандомизированы в 3 группы в соотношении 1:1:1: Мексидол 125 мг 2 раза в день, Мексидол 125 мг 1 раз в день+плацебо и плацебо. Продолжительность лечения во всех группах составила 42 дня. Исследование завершили 332 ребенка. Динамика состояния оценивалась по шкалам оценки СДВГ и сопутствующих расстройств. РЕЗУЛЬТАТЫ Получены статистически значимые изменения суммы общего балла по субшкалам «невнимательность», «гиперактивность/импульсивность» шкалы оценки СДВГ через 6 нед терапии во всех трех группах исследования (p<0,05). При этом между группами Мексидол 125 мг 1 раз в день+плацебо и плацебо, а также между группами Мексидол 125 мг 2 раза в день и плацебо наблюдались выраженные статистически значимые различия (для популяции PP: p=0,000308 и p=0,000024 соответственно; для популяции FAS: p=0,000198 и p=0,000024 соответственно), что свидетельствует о превосходстве терапии Мексидолом над плацебо. По большинству вторичных критериев эффективности (среднего изменения в баллах по субшкале «невнимательность» шкалы SNAP-IV, среднего изменения в баллах по субшкале «гиперактивность/импульсивность» шкалы SNAP-IV, среднего изменения в баллах по индексу Коннерса шкалы SNAP-IV, среднего изменения значения по шкале ADHD Rating Scale IV, оценки по шкале общего клинического впечатления степени тяжести СДВГ, оценки по шкале общего клинического впечатления – улучшение) также были получены статистически значимые отличия (p<0,05) при сравнении терапии Мексидолом с плацебо. Результаты статистического анализа частоты возникновения нежелательных явлений, показателей лабораторных анализов, физикального обследования демонстрируют отсутствие значимых различий между сравниваемыми группами по основным показателям безопасности. ЗАКЛЮЧЕНИЕ Схема лечения препаратом Мексидол таблетки, покрытые пленочной оболочкой, 125 мг 2 раза в день, показала преимущество перед схемой Мексидол таблетки, покрытые пленочной оболочкой, 125 мг 1 раз в день+плацебо. Был получен сопоставимый характер профилей безопасности исследуемых режимов дозирования препарата Мексидол и плацебо.

25 August 2018 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
AKAnastasiya Aleksandrovna Kozina
Anastasiya Aleksandrovna Kozina
EOElena Grigorievna Okuneva
Elena Grigorievna Okuneva
NBNatalia Vladimirovna Baryshnikova
Natalia Vladimirovna Baryshnikova
AKAnna Yurievna Krasnenko
Anna Yurievna Krasnenko
KTKirill Yurievich Tsukanov
Kirill Yurievich Tsukanov
VIValery Ilinsky
Valery Ilinsky
Neuronal ceroid lipofuscinoses (NCLs) are the most common autosomal recessive neurodegenerative disorders in children. Clinical manifestations include progressive cognitive decline, motor impairment, ataxia, visual loss, seizures and early death. To date more than 440 NCL-causing mutations in 13 genes are known. We report clinical and genetic characteristics of a 5-year-old girl affected by ceroid lipofuscinosis type 7 (NCL7). She had progressive motor and mental deterioration since the age of 2,5 years. Later she developed progressive vision loss, stereotypies, action myoclonus and epilepsy. By the age of 5 years she stopped walking. Based on symptoms, diagnosis of Rett syndrome was suggested, but no abnormalities were detected in MeCP2. We identified a novel homozygous mutation in MFSD8 gene (c.525 T > A, p.Cys175Ter). To our knowledge, this is the first report of MFSD8 gene mutation in a Russian patient with variant late-infantile NCL. Our results enlarge mutational spectrum of ceroid lipofuscinosis type 7 and demonstrate tremendous diagnosis value of exome sequencing for pediatric NCLs. Also we confirmed that NCL should be suspected in patients with Rett-like phenotype at onset and negative MECP2 mutation.

8 April 2019 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
KBKondakova Olga Borisovna
Kondakova Olga Borisovna
KYKrasnenko Anna Yurievna
Krasnenko Anna Yurievna
TYTsukanov Kirill Yurievich
Tsukanov Kirill Yurievich
KIKlimchuk Olesya Igorevna
Klimchuk Olesya Igorevna
KOKorostin Dmitriy Olegovich
Korostin Dmitriy Olegovich
VIValery Ilinsky
Valery Ilinsky
Dystroglycanopathies, which are caused by reduced glycosylation of alpha-dystroglycan, are a heterogeneous group of neurodegenerative disorders characterized by variable brain and skeletal muscle involvement. Muscle-eye-brain disease (or muscular dystrophy-dystroglycanopathy type 3 A) is an autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, and lissencephaly. We report clinical and genetic characteristics of a 6-year-old boy affected by muscular dystrophy-dystroglycanopathy. He has severe a delay in psychomotor and speech development, muscle hypotony, congenital myopia, partial atrophy of the optic nerve disc, increased level of creatine kinase, primary-muscle lesion, polymicrogyria, ventriculomegaly, hypoplasia of the corpus callosum, cysts of the cerebellum. Exome sequencing revealed compound heterozygous mutations in POMGNT1 gene (transcript NM_001243766.1): c.1539 + 1G > A and c.385C > T. The present case report shows diagnostic algorithm step by step and helps better understand the clinical and genetic features of congenital muscular dystrophy.

1 January 2017 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
AKA. L. Kurenkov
A. L. Kurenkov
OKO. A. Klochkova
O. A. Klochkova
BBB. I. Bursagova
B. I. Bursagova
HKH. M. Karimova
H. M. Karimova
LKL. M. Kuzenkova
L. M. Kuzenkova
МХМ. М. Хапаева
М. М. Хапаева
To assess the safety and clinical and neurophysiological efficacy of xeomin in children with spastic equinus and equinovarus foot deformity in cerebral palsy. Sixty-four patients with spastic forms of cerebral palsy (levels I-IV on the GMFCS) were enrolled into this multi-center open-label comparative randomized trial. The patients were administered xeomin or botox once, each drug being administered to 32 patients. Efficacy was evaluated based on clinical characteristics (the modified Ashworth scale, goniometry) and electromyography data. The subjects were observed for 3 months (90±7 days) after injections. The incidence, severity and intensity of adverse events (AE) was also determined. Treatment with xeomin according to the suggested protocol has proven its high clinical efficacy. The efficacy was demonstrated by significant, stable and long-term decrease in the gastrocnemius muscle tone: in the xeomin group, the score on the modified Ashworth scale decreased from 2.6±0.49 points at baseline to 1.8±0.54 points (р<0.000001, paired t-test; р<0.000004, Wilcoxon test). In the botox group, this score decreased from 2.4±0.56 points to 1.6±0.45 points (р<0.000001, paired t-test; р<0.000002, Wilcoxon test). The increased range of ankle joint movements at passive and voluntary feet extension. In the xeomin group, the significant proportion of patients (45.1%) moved to the group of lower spasticity defined as less than two score points on the modified Ashworth scale. The clinical data fully matched the changes in electromyography parameters, which were characterized by the lower amplitude and area of the target muscle (lateral and medial gastrocnemius heads) M-responses. AE developed in three patients (9.4%) administered xeomin and in two patients (6.3%) administered botox. The AE recorded in the study are described in the recommendations on the use of xeomin and botox. In three cases (50.0%), AE intensity was determined as mild, in the remaining three cases (50.0%) as moderate. The results have shown the safety and efficacy of xeomin in the treatment of gastrocnemius spasticity in pediatric patients with cerebral palsy. These data are confirmed by the lack of significant differences in any clinical or electromyography parameters with the results in the reference group administered botox.

1 January 2016 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
EPE. V. Popova
E. V. Popova
ABA. N. Boyko
A. N. Boyko
OBO. V. Bykova
O. V. Bykova
INI. G. Nankina
I. G. Nankina
TBTatyana Batysheva
Tatyana Batysheva

30 September 2024 in Российский психологический журнал
Verified
Journal Article
Open access
PDF file
ЛШЛюдмила А. Шайгерова
Людмила А. Шайгерова
АБАлексей М. Букинич
Алексей М. Букинич
АДАлександра Г. Долгих
Александра Г. Долгих
TBTatyana Batysheva
Tatyana Batysheva
Introduction. This article analyzes various aspects of psychological well-being and resources for mothers of children with autism spectrum disorder (ASD) who have been displaced from their permanent residence. Methods. Mothers of children with ASD, the main group (N = 18, mean age 39.9 years) who live with their children in a temporary accommodation center (TAC) and the control group (N = 18, mean age 32.9 years) participated in the study. The abbreviated Depression, Anxiety, and Stress Scale (Lovibond, Lovibond, 1995), Multidimensional Scale of Perceived Social Support (Zimet et al., 1988), Frequency of seeking help in different categories (Ushkov et al., 2020), Modified Semantic Differential methodology (Molchanov, Almazova, Poskrebysheva, 2023), Coping Ways Scale, Single-item assessment of general life satisfaction were used. Results. Forced migrants demonstrated lower life satisfaction, weaker perception from friends and in general from different sources, more often ready to seek help from "secondary support" groups, and less often from partners and friends compared to the control group. No differences were found between the groups in measures of depression, anxiety, and stress, but the levels of depression and stress were significantly higher in both groups compared to the population data. Differences in time perspective were found: forced migrants perceive the world in the future as less complicated compared to the control group. Discussion. The peculiarities of psychological well-being (increased levels of stress and depression) due to the presence of children with ASD, characteristic of both groups, and differences between groups determined by forced migration were revealed. Important resources for migrants may be a positive image of the world in the future, readiness to rely on support from family and "secondary support" groups, and some sociodemographic characteristics (presence of other children, age). Conclusion. The results obtained will make it possible to pay special attention to those categories of forced migrants who were previously in risk groups, including mothers of children with mental developmental disabilities.